Robert Alter, MD
Medical Oncology · Hackensack, NJNPI 1306805460
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 17.7%. Among medical oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 967 payments — averaging $239.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$41K
- Bayer$38K
- Astellas Pharma US Inc$34K
- EMD Serono, Inc.$23K
- Johnson & Johnson$20K
- Exelixis Inc.$20K
- plus $56K from 47 others
Across 658 payments — averaging $6500.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.2M
- Pfizer$1.1M
- Seagen Inc.$476K
- E.r. Squibb & Sons, L.L.C.$88K
- Exelixis Inc.$78K
- Incyte Corporation$60K
- plus $277K from 12 others
What the payments were for
- Consulting fees$121,37252%
- Speaking & faculty fees$79,10334%
- Travel & lodging$15,8977%
- Food & beverage$13,9136%
- Education$1,6721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$231,958 in reported general payments places this provider in the 90th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 91 | $1,628,533 |
| XtandiEnzalutamide | 104 | $1,243,844 |
| NubeqaDarolutamide | 92 | $1,164,223 |
| LenvimaLenvatinib Mesylate | 49 | $1,158,610 |
| InlytaAxitinib | 39 | $675,074 |
| WeliregBelzutifan | 20 | $584,994 |
| Abiraterone Acetate | 454 | $560,232 |
| ErleadaApalutamide | 51 | $554,731 |
| TalzennaTalazoparib Tosylate | 24 | $440,967 |
| MekinistTrametinib Dimethyl Sulfoxide | 15 | $208,685 |
| LynparzaOlaparib | 15 | $170,828 |
| OrgovyxRelugolix | 59 | $146,842 |
| EliquisApixaban | 38 | $22,505 |
| XareltoRivaroxaban | 16 | $12,691 |
| Anagrelide Hcl | 15 | $6,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $19,729 | $1,628,53391 claims |
| Astellas Pharma US IncXtandi | $34,414 | $1,243,844104 claims |
| BayerNubeqa | $37,553 | $1,164,22392 claims |
| Eisai Inc.Lenvima | $41,095 | $1,158,61049 claims |
| PfizerInlyta, Talzenna, Eliquis | $17,954 | $1,138,547101 claims |
| MerckWelireg | $941 | $584,99420 claims |
| Johnson & JohnsonErleada, Xarelto | $20,200 | $567,42267 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $758 | $560,232454 claims |
| NovartisMekinist | $4,629 | $208,68515 claims |
| AstraZenecaLynparza | $8,641 | $170,82815 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $2,925 | $146,84259 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $53878 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackensack
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
- Andrew IpHackensack$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.